Advertisement
Skip to Content

Eli Lilly and Co LLY Stock Quote

| Rating as of

NYSE: LLY

Last close prices updated as of Jun 09, 2023, 7:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 446.04
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Growth
  • Day Range 442.60  –  449.30
  • Year Range 283.11  –  454.95
  • Market Cap 423.4137 Bil
  • Volume / Avg 2.1 Mil /  3.2 Mil
  • Price / Sales 14.56
  • Price / Book 37.84
  • Forward Div Yield 1.01%
  • Trailing Div Yield 0.95%

Morningstar‘s Stock Analysis LLY

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Novo Nordisk and Eli Lilly Lead Potential $60 Billion Obesity Drug Market; Valuations Look Rich

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

The approval of Novo Nordisk's GLP-1 agonist Wegovy in 2021 has led to a demand surge for the active ingredient semaglutide in various forms, including diabetes drug Ozempic. Eli Lilly's approved diabetes drug Mounjaro is poised to generate even stronger weight loss and to launch in obesity around the end of 2023. We think Novo and Lilly will continue to lead the obesity market over the next 10 years, with incremental innovation in this rapidly expanding market that will support their wide moats. We assume Novo Nordisk's Wegovy, higher-dose oral and injectable semaglutide, and novel GLP-1/amylin cagrisema will support more than 35% share in 2032. Eli Lilly is likely to remain Novo's chief competitor, driven by potential launches of Mounjaro in obesity as well as an oral GLP-1 and a novel triple agonist in 2025, resulting in a 40% share by 2032. We think Amgen, Pfizer, and other biopharma firms could begin to launch their own GLP-1-based obesity drugs as early as 2025, with these new players growing to roughly one quarter of the market by 2032.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics LLY

Company Profile LLY

Business Description

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact
Lilly Corporate Center
Indianapolis, IN, 46285
Industry Drug Manufacturers - General
Employees 39,000

Related Articles LLY

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of LLY’s competitive advantage.

Eli Lilly and Co

XNYS: LLY

Bristol-Myers Squibb Co

XNYS: BMY

Merck & Co Inc

XNYS: MRK

Novo Nordisk A/S Class B

XCSE: NOVO B
Price
446.0464.80110.711,091.60
Currency
USDUSDUSDDKK
Change
+$0.38 (0.09%) −$0.51 (0.78%) +$0.39 (0.35%) −$7.40 (0.67%)
Market Cap
423.41 Bil136.13 Bil280.92 Bil2.45 Tril
Industry
Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General Biotechnology
Sector
Healthcare
Healthcare
Healthcare
Healthcare

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Eli Lilly and Co Stock

Yes. LLY has a forward dividend yield of 1.01%. See LLY’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

LLY’s market cap is 423.41 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

LLY’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

LLY’s price/sales is 14.56.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

LLY’s price/forward earnings is 70.91.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

LLY’s price/book is 37.84.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See LLY’s valuation ratios compared to the Market Index.

LLY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare LLY’s historical performance against its industry peers and the overall market.